Liver cancer trial tests combo therapy against single drug
NCT ID NCT07408804
First seen Feb 25, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study tests whether adding a targeted procedure (TACE) to a standard drug (lenvatinib) works better than the drug alone for people with liver cancer that cannot be removed by surgery. About 40 adults aged 18-75 with early to advanced liver cancer will be enrolled. The main goal is to see if the combination shrinks tumors more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hepatology, Bangladesh Medical University
RECRUITINGDhaka, 1000, Bangladesh
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.